Search Weight Loss Topics:

Page 1,627«..1020..1,6261,6271,6281,629..1,6401,650..»

Home » Page 1627

FlexIt

FlexIt enables users to only pay for the gym time they use

FlexIt

FlexIt allows app users to pay for fitness club use by the minute, bringing a new access point to consumers in the region

DALLAS, Dec. 04, 2019 (GLOBE NEWSWIRE) -- FlexIt, the mobile-app that enables users to only pay for the gym time they use, today announces a new partnership with Texas Family Fitness, providing users in the Dallas-Fort Worth area with the ability to work out at clubs seamlessly. Starting immediately, FlexIt users now have access to all 12 Texas Family Fitness locations from Denton to Garland, including the newest preview workout center in Lakewood.

The core mission of Texas Family Fitness truly aligns with our goals here at FlexIt providing a seamless workout experience available to each member of the community, from beginners to experienced athletes, said Austin Cohen, CEO and Founder of FlexIt. The pairing of FlexIt and Texas Family Fitness allows more residents and visitors to the community to access the facilities in a manner that is most convenient and comfortable for them in line with consumption trends and preferences.

Within the app, FlexIts proprietary software and sleek interface allows users a seamless check-in and check-out experience in a non-intimidating manner users simply scan the QR mount at the front desk to start their workouts and then scan the code again when they are done working out, enabling them to pay only for the time they work out. FlexIt also recently announced its augmented reality technology, which will enable users to tour clubs in advance of visiting the facilities, so as to make the experience as frictionless as possible.

Texas Family Fitness is excited to launch a partnership with FlexIt to continue providing top-notch fitness experiences to our members and the community, said Josh Wheeler, CEO of Texas Family Fitness. TFF prides itself on delivering tremendous member satisfaction and FlexIt will help extend that to the users they serve. With 12 locations and growing throughout DFW, we are excited to welcome all FlexIt users to our Family.

I visited nearly all of the Texas Family Fitness clubs and know current users and new users will be thrilled with what this fast-growing chain has to offer, said Justin Turetsky, Founding Partner heading up Operations. These clubs have great classes, amenities and unique blue turf areas coupled with a welcoming family atmosphere. You can actually watch your child on screens while you get your workout in. With FlexIt, you can try these clubs, by-the-minute, on your terms.

Texas Family Fitness has 12 locations in the Dallas-Fort Worth area, all complete with state-of-the-art equipment, a variety of group classes and Kids Clubs so parents and guardians can make me time a priority. Most recently, Texas Family Fitness opened brand new locations in Garland and Lewisville both equipped with oversized cardio centers, personal training, Ignite group training and large free-weight areas. Texas Family Fitness preview workout center is is open in Lakewood with the full gym opening early 2020.

With the addition of Texas Family Fitness, the app currently hosts over 1,000 gyms around the country and is available for download in the App Store and Google Play. To learn more about FlexIt, visit: http://www.flexit.fit.

About FlexItFlexIt Inc. is the mobile app that quickly and seamlessly enables users to access a wide network of fitness clubs around the U.S., paying only for the amount of time that they are in the facility. With over 1,000 fitness clubs across the country in its network, FlexIt offers consumers the flexibility that they expect, while generating leads and enhancing profitability for fitness clubs. FlexIt provides club access to users while simultaneously providing clubs with access to a large network of prospective members. FlexIt is available for download on iOS and Android in their respective app stores. For more information, please visit https://www.flexit.fit/

About Texas Family FitnessFor 15 years now, Texas Family Fitness is the affordable fitness solution for the Dallas-Fort Worth area. Our unique approach to fitness focuses on achieving our members goals by proper nutrition, accountability, supplementation and exercise. Texas Family Fitness prides itself on having an educated staff and state-of-the-art facilities focused on member satisfaction. Our family friendly environment is welcoming to all levels of fitness. Whether you are an avid lifter or just beginning your fitness journey, we welcome you as part of ourFamily.

Media Contact:Lauren CozzaUproar PR for FlexItlcozza@uproarpr.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ca0d07ba-df09-441a-bca6-efa40bdeb9b7

See the rest here:
FlexIt Announces Partnership with Texas Family Fitness to Bring Convenient Fitness to the Greater Dallas-Fort Worth Area - GlobeNewswire

Read More..

You know that exercise can help you be fit, increase your energy, avoid obesity and significantly reduce your risk of many chronic complications. A regular fitness routine can also help you avoid mental health issues, improve sleep and give a boost to your sex life.

Regular exercise is a must if you wish to stay fit and healthy. There is no alternative to it. You see the benefits immediately after starting any exercise routine. But how do you start? It is easier said than done. You have made up your mind and determination is there. But most people tend to procrastinate and delay the inevitable. But when you really get down to it, you may feel lazy and give up after a few days. No doubt, it takes a lot of discipline and determination to exercise regularly. Our fitness expert and yoga trainer, Hina Kumari, shows you the way forward in this video. Watch the video to know the beginners exercises that will put you on the right track.

Things to keep in mind before you start on your fitness routine

Choose a fitness routine that will help you stay on course. Be realistic about your goals. This is very important. Also, if you have any health complications, consult your doctor first. He will be able to guide you to a good and safe beginning. Start slow and gradually build up intensity. Everybody leads busy lives nowadays. So, time is always a problem. Set aside a time for exercise and stick to it. If you cant manage an hour, make it 30 or even 15 minutes. But do it every day. This will make it a habit and you will start to miss your sessions if you miss it.

A very common mistake most beginners make is that they go overboard. This increases the risk of injuries. Just remember that anything in excess is not good for health. The same is the case with exercise. You may also give yourself an off day. This will help you help you come back to your fitness routine with renewed vigour.

Fitness routine tips for beginners

Beginners are often clueless when it comes to starting their fitness routine. Most people make the mistake of rushing headlong into their regime without a thought. This is wrong. Exercising is serious business and you must approach it as such. You must also take proper care of yourself if you want to get maximum benefits.

Drink a lot of water through the day. This is help you avoid dehydration when you sweat it out during your fitness routine.

Eat healthy meals. This will support your fitness routine. Have proper, well-balanced meals that also include generous serving of fruits and vegetables.

Add healthy carbs to your diet. This will aid muscle recovery and increase your energy levels.

Have a lot of proteins. These too helps in muscle recovery. It will also facilitate faster healing of tissues and building of muscle mass.

All fats are not bad. Healthy fats can actually help you burn fat faster. It will also increase energy levels and help you work out for a longer duration.

Warming up before your fitness routine is very important because it will help you avoid the risk of injuries. It will also improve flexibility.

Published : December 6, 2019 6:29 pm

Go here to see the original:
Want to start a fitness routine? A few pointers to help you along - TheHealthSite

Read More..

Are you ready for testosterone replacement therapy?

It is well known that testosterone plays a role in a mans sex drive, but this vital hormone does more than regulate libido and sperm production. It also has a role in regulating systems throughout the body.

It also affects bone and muscle mass, the way men store fat in the body, and even red blood cell production, according to Healthline. A mans testosterone levels can also affect his mood.

Symptoms of declining testosterone

Testosterone production maxes out in most men around age 17, and then levels stay relatively consistent for the next 10 to 20 years. Sometime between ages 30 and 40, its normal for men to experience a slow decline in testosterone production, averaging about 1% a year, according to Harvard Health.

You lose muscle mass, mental sharpness and libido (sex drive) begins to decline, viTal4men says.

Benefits of testosterone

Research has pinpointed other links between testosterone levels and memory. One study cited by Harvard Health found that World War II veterans who had high testosterone levels in midlife had better preserved tissue in some parts of the brain later in life.

Another study found that men with higher free testosterone levels achieved higher scores on four cognitive function tests, including visual and verbal memory, according to Harvard Health.

Testosterone replacement therapy aims to address the symptoms men experience from low testosterone levels and possibly help protect cognitive function in later life.

You may benefit from testosterone replacement therapy if any of the following apply:

Treatment options

The proper method of testosterone delivery for you is a matter for your physician to determine; however, many find that some gels tend to be messy and less convenient than other treatment modalities, viTal4men says.

These are typical treatment options, according to Harvard Health:

Most men feel improvement in symptoms within four to six weeks of taking testosterone replacement therapy, although changes like increases in muscle mass may take from three to six months, Harvard Health says.

Work with your doctor to find out whether you are experiencing symptoms of low testosterone. Misuse of testosterone can be dangerous, and injections should be administered only by healthcare professionals. Suddenly stopping testosterone treatment can also cause unpleasant withdrawal symptoms, according to drugs.com.

Schedule a free testosterone level test at vital4men.com, and find out if testosterone replacement therapy is right for you.

Continued here:
Are you ready for testosterone replacement therapy? - KTAR.com

Read More..

Treatment with Myovant Sciences relugolix induces a long-lasting reduction in testosterone to castrate levels similar to testosterone levels after medical or chemical castration in nearly all men with advanced prostate cancer who are sensitive to androgen deprivation therapy, updated results from the HERO Phase 3 trial show.In addition to meeting its primary goal sustained castration from weeks 5 to 48 of treatment the trial met six additional secondary goals. These included a faster testosterone suppression than standard treatment with leuprolide acetate, and a rapid drop in prostate specific antigen levels, which are a marker of prostate cancer.The results will support the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2020, as well as submissions to Japan's and Europe's regulatory agencies.With the exciting results from the HERO study demonstrating the potential of relugolix to provide unique benefits compared to leuprolide, we look forward to submitting an NDA to the FDA, Lynn Seely, MD, president and CEO of Myovant Sciences, said in a press release. We are now closer to our goal of bringing a precision oral medicine to the br

More:
Relugolix Induces Sustained Testosterone Reduction in Advanced PC, Phase 3 Trial Results Show - Prostate Cancer News Today

Read More..

Over a long career that stretches back 25 years, stuntman and stunt coordinator-turned-second-unit-director and actor Darrin Prescott has choreographed many a spectacular car chase and race in such testosterone-fueled movies as Drive, Deadpool 2, Baby Driver and The Bourne Ultimatum, which won him a Screen Actors Guild award as part of the stunt ensemble.

But when director James Mangold called him up to play famous racer Bob Bondurant and supervise the second-unit action crew for Ford v Ferrari, he knew itd be a special job.

He loved what wed done on Baby Driver, and when I asked him how we were going to handle all the classic race cars on this, he just said, Were going to build em, Prescott says.

This was music to Prescotts ears, as Ford v Ferrari chronicles the story of race car legends Carroll Shelby (Matt Damon) and Ken Miles (Christian Bale) and culminates in the historic showdown between the Ford Motor Co. and legendary Ferrari at the grueling 1966 24-hour Le Mans race in France. Those cars are now priceless museum pieces, so high-performance replicas had to be built.

We rarely get the opportunity to build cars like these, Prescott says. Usually, when I get a call like this, they always have big eyes. They always tell you theres going to be McLarens and Lamborghinis, and ultimately you end up with Corvettes and some sort of product placement. But they actually pulled it off and delivered this time.

Coupled with Mangolds determination to use real cars was his plan to re-create and shoot the famous Le Mans race all in camera, rather than using CGI, says Prescott. That presented quite a few big challenges. The first and biggest was that the original Le Mans course doesnt exist anymore or at least, nothing like it used to be.

The filmmakers used several locations in Georgia to double for Le Mans in the films climactic sequence, which lasts some 40 minutes. So we had to tie all those locations together to make it all as seamless as possible, he says. And then Jim wanted to make sure we maintained an authentic camera style. He didnt want any big swooping camera moves and any hint of the beauty shot approach you see in all the car commercials. And because the cars were exact period replicas, there was very little room to mount cameras and roll cages in them.

With all the restrictions, Prescott and his core team, which included stunt coordinators Robert Nagle and Jeremy Fry (also a driver), focused on sheer speed and storytelling. Every shot had a purpose, and sometimes on second unit and with action its easy to forget all that, he says. But Jim was adamant about that, more so than anyone else Ive ever worked with.

Prescott shot wide-angle anamorphic for eight weeks using a team of a dozen professional drivers, some of whom had actually won Le Mans, he says. With the anamorphic lenses, we had to cram the cars right up into the lens maybe just six inches from camera, which you can only achieve with drivers of that caliber. On top of that, the cars are so close to each other and theyd be doing 140 mph with the camera car inches off their nose. But the truth is, they actually had to dumb it down. It was nothing to these guys as theyre used to going 200 mph.But few crew members were used to racing in the sweltering heat and humidity of a Georgia summer. They had to wear these special, iced cool suits, as the track pavement temperature was 140 degrees, Prescott says. That was almost the hardest part of the whole shoot.

Read more from the original source:
Ford v Ferrari Race Re-Creations Better Than The Real Thing - Variety

Read More..

CultureArtsOf all the groups you probably wouldnt want to be part of, the hyper-adrenalised, hardscrabble populace of Jordan Belfort's memoir is one

Friday, 29th November 2019, 4:42 pm

The Wolf of Wall Street Immersive Experience, Sun Street, London,

Of all the groups you probably wouldnt want to be part of, surely the hyper-adrenalised, hardscrabble populace of The Wolf of Wall Street, the Jordan Belfort memoir made into an amphetamine rush of a film by Martin Scorsese in 2013, must rank near the very top. And yet here, against expectation, is an immersive theatre adaptation. Whats more, it is being staged just a coke-fuelled trot from Londons City equivalent of the do-or-die New York milieu from which Belfort has since emerged, post-imprisonment, as some sort of anti-heroic guru.

And if your response to the very fact of this show is, Why?, well, join the club. Whereas writer-director Alexander Wright hit paydirt with an ongoing, comparably immersive Great Gatsby, a story that allows for lots of fancy-dress shenanigans, whats the appeal of losing the celluloid filter between us and Jordan and his money-mad acolytes? Not long into the (overlong) scenario, I had a puzzling sense of dj vu until I realised that I hadnt experienced such barely contained testosterone since I found myself some years back on a flight to Prague with a stag party. (The same group was virtually comatose on the flight back.)

Theres little chance of nodding off here once events indoctrinate us into the code of omert (mispronounced, by the way) at the stock-trading firm of Stratton Oakmont, where Belfort made his fortune before his fall from grace. Asked to drop to our knees (at which point, cue any number of unprintable follow-ons), we then pursue one of several different storylines, or tracks, across 27 rooms watched over by various minders in case things get a bit too, um, frisky. New York-style hot dogs are on sale to ramp up an authenticity not always evident in the wearisomely Goodfellas-esque accents.

I ended up pursuing the domestic narrative, which meant making the acquaintance of the amiable Rhiannon Harper-Raffertys Nadine, wife to Oliver Tilneys hardworking but strangely absent Jordan and mother to their seven-year-old daughter Chandler, played at the performance by the adorable, apparently unfazed Suri De Jesus: one assumes she isnt within earshot when her onstage mum is described as having a delectable vagina.

Lest proceedings be seen to be too in love with a monstrous world from which most of us would run a mile, my fellow playgoers were given a moralistic, virtue-signalling finish that may or may not find an equivalent in the other stories going on elsewhere in the building. At the end, you can grab a drink and mingle with the very lovely cast: the actors I met seemed lightyears removed from the venal environs they must inhabit seven times a week, and praise be for that. THEARTSDESK.COM

View post:
The Wolf of Wall Street Immersive Experience, review: an overlong scenario with the barely contained testosterone of a stag party - inews

Read More..

ENGLEWOOD, CO / ACCESSWIRE / December 5, 2019 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced that MiOXSYS will be featured in a Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and Medicine held December 5-7, 2019 in Leipzig, Germany.

During the symposium, multiple clinical presentations featuring the MiOXSYS System will be made Friday, December 6, 2019 by leading andrologists and reproductive medicine experts from around the world. Professor Christian Schuppe, Professor and Chair of Urology at the University of Giessen, will chair the symposium.

The Product Symposium will be conducted at 10:30 AM CET at the Kongreshalle am Zoo Leipzig, Schiller Room.

Symposium Presenters & Presentations:

Moderator: Professor Dr. med. Hans-Christian SchuppeClinic and Policlinic for Urology, Pediatric Urology and AndrologyUniversity Hospital Giessen und Marburg (UKGM) - GiessenGiessen, Germany

Presentation I: Oxidative Stress in Semen: Causes, Diagnosis and Significance for Assisted Reproduction

Presenter: Professor Dr. Ralf Henkel, PhD.Department of Medical BioscienceUniversity of the Western CapeBellville, South Africa

Presentation II: Sperm in Danger: Oxidative Stress and Inflammation

Presenter: Professor Dr. med. Jean-Pierre AllamClinic and Policlinic for of Dermatology and AllergyUniversity Hospital Bonn (UKB)Bonn, Germany

The MiOXSYS System is currently in use in over thirty countries around the world and is CE Marked and cleared by Health Canada, the Australian Therapeutic Goods Administration (TGA), and Mexico's COFEPRAS.

Hosting of this Product Showcase does not imply endorsement of the MiOXSYS System by German Federation of Reproductive Biology and Medicine Congress.

About Aytu BioScience, Inc.

Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex Sprinkle, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the effects of the business combination of Aytu and the Commercial Portfolio and the previously announced, but not yet consummated, merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, the failure to obtain the required votes of Innovus' shareholders or Aytu's shareholders to approve the Merger and related matters, the risk that a condition to closing of the Merger may not be satisfied, that either party may terminate the merger agreement or that the closing of the Merger might be delayed or not occur at all, the price per share utilized in the formula for the initial $8 million merger consideration in the Merger may not be reflective of the current market price of Aytu's common stock on the closing date, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Story continues

Originally posted here:
MiOXSYS Male Infertility Test Will be Featured in Product Symposium at the 8th Annual Congress of the German Federation of Reproductive Biology and...

Read More..

TORONTO Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the revised commercial partnership agreement with Aytu Bioscience (Aytu) to accelerate the growth of NATESTO in the United States is now closed and fully effective as of December 1, 2019. Both parties have mutually waived the closing conditions of the revised partnership agreement, including the requirement that Acerus complete a raise of a minimum of USD 10 million on or before the end of January 2020, enabling Acerus to launch a U.S.-based specialty sales force, which will promote NATESTO to urologists and endocrinologists. Aytu will continue to book all NATESTO revenue in the United States and they will promote NATESTO to all other specialties including internal medicine and family practice.

To accelerate the launch of Acerus U.S. commercial team, Aytu has agreed to transfer 5 current sales personnel to Acerus as of December 2, 2019. These staff will operate as Acerus employees but they will remain on Aytus payroll until the earlier of the date on which Acerus is ready to fully assume the personnel or June 30, 2020. Aytu will deduct the costs of these sales personnel from quarterly payments otherwise owed to Acerus under the revised agreement, with a final accounting to be done once per year. Throughout 2020, Acerus will be building out a complete US-based specialty care sales force and other commercial functions, significantly increasing the number of employees working directly on NATESTO in the United States.

This co-promotion is expected to significantly increase sales force coverage of targeted U.S. prescribers, putting a higher promotional focus on urologists and endocrinologists, while enabling Aytu to focus its promotional efforts in primary care and other specialties.

Acerus is extremely pleased to see our revised partnership with Aytu moving to execution mode as we strongly believe that the performance of NATESTO in the U.S. will benefit from an enhanced commercial focus on urology and endocrinology, said Ed Gudaitis, President and Chief Executive Officer of Acerus. We are happy to welcome the former Aytu staff to the Acerus team. With this revised partnership, Acerus is effectively pivoting its focus of effort to the U.S. NATESTO opportunity. As such, we have implemented a resource reallocation program within our Canadian office that has led to a greater than 50% reduction in headcount so that we can align our SG&A spend appropriately.

On July 29, 2019 the companies agreed to expand their commercial partnership and amend and restate the original 2016 NATESTO exclusive U.S. license agreement. Under the terms of the new agreement, Aytu returns the NDA for NATESTO in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel). Aytu will retain its primary care sales force (Aytu Sales Channel) and will continue to book all product net revenue while serving as the exclusive U.S. supplier of NATESTO to wholesalers, pharmacies and other customers that receive a direct shipment. Financial payments will be based upon a tiered level of net revenue, post cost of goods sold (COGS), based on annual sales performance in the respective Acerus and Aytu Sales Channels.

To establish a high performing commercial footprint in the U.S., Acerus has engaged Syneos Health (NASDAQ: SYNH), a leading integrated biopharmaceutical solutions organization including the industrys largest Contract Commercial Organization (CCO), to be its commercialization partner. Syneos Health has extensive experience in Mens Health and with NATESTO, and offers an end-to-end model that will enable Acerus to rapidly stand up a U.S. commercial team; to scale across all aspects of commercialization, including medical and regulatory affairs, managed markets, marketing and sales; and will provide greater flexibility and effectiveness in resource deployment.

Low testosterone is estimated to affect approximately 39% of men over 45 years old in the U.S.; however, because the condition is underdiagnosed the overall prevalence is uncertain1. While patients have access to other treatment options, NATESTO is unique in that it is administered in seconds via a convenient and simple nasal gel applicator, addressing the risk of testosterone transference associated with other topical products, which carry black box warnings on their product labels.

About NATESTO (Testosterone) Nasal Gel

NATESTO is a nasal gel formulation of testosterone developed by Acerus Pharmaceutical Corporation and indicated as a replacement therapy for men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). It is the first and only nasally-administered testosterone product approved by the U.S. Food and Drug Administration, Health Canada and South Korea Ministry of Food and Drug Safety (MFDS), available in a no-touch dispenser with a metered dose pump. A copy of the NATESTO Canadian product monograph can be found at: http://www.aceruspharma.com/English/products-and-pipeline/NATESTO /default.aspx. For further information, specific to the U.S. product dosing and administration, please visit: http://www.NATESTO .com.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of mens health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Acerus shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit http://www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO in the United States, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 which is available at http://www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

1 Mulligan T, Frick MF, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul 1; 60(7): 762769

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005215/en/

Contacts

Media: Edward Gudaitis President and Chief Executive Officer egudaitis@aceruspharma.com (905) 817-8194

Read the original:
Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational - Financial Post

Read More..

Youve been on the pill since high school. Its served its purpose of preventing pregnancy, but do you really know what its done beyond that? You might want to pick up a copy of This Is Your Brain on Birth Control, a new book by Sarah E. Hill, PhD. Dr. Hill is a researcher in evolutionary biology as well as a professor at Texas Christian University.

According to Dr. Hill, although women go on the pill for a few reasons (chief among them pregnancy prevention and clearer skin), sex hormones dont work in such isolated ways. Translation: Sex hormones impact the activities of billions of cells in the body at once, many of which are in the brain. That means playing around with your sex hormones via the birth control pill can influence attraction, sexual motivation, stress, hunger, eating patterns, emotion regulation, friendships, aggression, mood, learning and more. This Is Your Brain on Birth Control seeks to make women aware of everything the pill is doing beyond preventing pregnancy and improving skin.

A few things to note: First, Dr. Hillmakes it very clear that shes completely pro-birthcontrol, and even attributes getting her PhDand having children when she was readytobeing on the pill. She doesnt suggest that women stop taking the pill, nor does she refute the revolutionary effect the pill continues to haveonwomens personal and professional lives. Second, Dr. Hill recognizes that while her book (and much of the research on birth control) is focused on heterosexual cisgender women, shes not discounting the experience of other female-identifying folks who arent on the pill. Read on for three surprising ways being on the pill can affect your life.

RELATED: Which Birth Control Is Right for Me? Every Single Method, Explained

One of the most fascinating points in Dr. Hills book is that the pill can impact the type of partner youre attracted to. Scientists have only recently started to explore this possibility. And although this research is new and the results are mixed, the picture that is beginning to emerge is fascinating. They suggest that the birth control pill might influence everything ranging from whom you pick as your partner to the likelihood that youll get divorced. This can manifest in a number of ways, but it may mean that if youve been on the pill for a long time, find a partner, date that partner for a long time and then go off of the pill, you might see them in a different light once your hormones are responsible for regulating themselves.

Because women on the pill dont ovulate, they dont experience the pre-ovulatory estrogen surge that increases attention to markers of genetic quality in men. What does that mean, exactly? While women who arent on the pill experience a spike in their attraction to men with strong jaws, deep voices and other traditional testosterone markers while their estrogen levels are high (typically mid-cycle), women who are on the pill will probably place less emphasis on sex appeal when choosing a partner.

Considerable research finds that women on the pill have lower sexual desire than what is observed in naturally cycling women. Why? The pill suppresses the hormonal cascade that sets in motion the release of a mature egg. Along with that hormonal cascade comes a surge of estrogen thats known to fuel womens desire for sex. The pill can also cause womens levels of testosterone to steeply decline. (Testosterone plays a role in sexual arousal and responsiveness.) Since a lack of sex drive can be a major source of stress in a womans life and relationship, Dr. Hill suggests being gentle with yourself if you find yourself in this situation. Be patient with yourself and your partner as you work together to troubleshoot your birth control options, she writes. The solution might be as simple as finding a new doctor, a new pill or a different form of birth control.

RELATED: We Ask a Derm: How Do I Go Off Birth Control Without Breaking Out?

Read this article:
The Pill Can Make You Less Attracted to Jerks, and Other Surprising Facts About Birth Control - Yahoo Lifestyle

Read More..

Global Testosterone Replacement Therapy Market Research Report comprises holistic business information and changing trends in the market that enables users to spot the pin-point analysis of the market along with revenue, growth, and profit during the forecast period 2019-2024. It provides an in-depth study of the Testosterone Replacement Therapy market by using a SWOT analysis. This gives a complete analysis of drivers, restraints, and opportunities of the market.

Additionally, the Testosterone Replacement Therapy report provides an in-depth study of prime players at intervals the market by lightness their product description, business summary, and business strategy. It also endows with the quantity of production, Testosterone Replacement Therapy future demand, required raw material, and the money health of the organization.

Request a sample of this report at https://www.acquiremarketresearch.com/sample-request/229964/

Top prominent Players: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

By the Product-Types, it primarily split into: Gels, Injections, Patches

By End-Users/Application, this report covers: Hospitals, Clinics

Based on segmentation, the global Testosterone Replacement Therapy market report is made up of in-depth investigation of the leading regions, including North America, China, and Rest of Asia-Pacific, UK, Europe, Central & South America, and Middle East & Africa. The Testosterone Replacement Therapy research was provided for, including developments, leading growth status, landscape analysis, and segmentation with product types and applications.

Get Discount with this Report at https://www.acquiremarketresearch.com/discount-request/229964/

Reasons to Buy

1. To gain insightful analyses of the Testosterone Replacement Therapy Systems market from 2019 to 2024 and have a comprehensive understanding of the global market and its commercial landscape.2. To assess the production processes, Testosterone Replacement Therapy major issues, and solutions to mitigate the development risk.3. To understand the most affecting driving and restraining forces in the Testosterone Replacement Therapy Systems market from 2019 to 2024 and its impact in the global market.4. To understand the future outlook and prospects for the Testosterone Replacement Therapy Systems market from 2019 to 2024.

The report additionally focuses on international major leading trade players of the world Testosterone Replacement Therapy market providing data like company profiles, product image, and specification, price, capacity, cost, production, revenue and call data.

Upstream raw materials and instrumentality and downstream demand analysis are additionally administrated. With tables and figures helping analyze the worldwide Testosterone Replacement Therapy market, this research provides Testosterone Replacement Therapy statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Customization of this Report: This Testosterone Replacement Therapy report could be customized to the customers requirements. Please contact our sales professional [emailprotected], we will ensure you obtain the report which works for your needs.

Read more here:
Testosterone Replacement Therapy Market Share, Size 2019 Global Industry Analysis, Development, Future Growth, Top Manufacture, Revenue,...

Read More..

Contact Us Today

Page 1,627«..1020..1,6261,6271,6281,629..1,6401,650..»

Home » Page 1627